

Jesper G Eriksen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2943440/jesper-g-eriksen-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

2,518
citations

24
h-index

49
g-index

85
ext. papers

2,996
ext. citations

3.1
avg, IF

4.87
L-index

#	Paper	IF	Citations
78	Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts. <i>International Journal of Cancer</i> , 2021 ,	7.5	1
77	The ESSO core curriculum committee update on surgical oncology. <i>European Journal of Surgical Oncology</i> , 2021 , 47, e1-e30	3.6	1
76	Surgical treatment of the neck in patients with salivary gland carcinoma. <i>Head and Neck</i> , 2021 , 43, 1898-1911	4.1	5
75	Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database. <i>British Journal of Cancer</i> , 2021 , 125, 458-464	8.7	1
74	Reply to Letter to the Editor regarding "Elective neck dissection and its extent in Salivary gland cancers: A Dilemma". <i>Head and Neck</i> , 2021 , 43, 2861-2862	4.2	
73	Comparing different CT, PET and MRI multi-modality image combinations for deep learning-based head and neck tumor segmentation. <i>Acta Oncologica</i> , 2021 , 60, 1399-1406	3.2	7
72	Imaging for Target Delineation in Head and Neck Cancer Radiotherapy. <i>Seminars in Nuclear Medicine</i> , 2021 , 51, 59-67	5.4	6
71	Early Mortality after Radical Radiotherapy in Head and Neck Cancer - A Nationwide Analysis from the Danish Head and Neck Cancer Group (DAHANCA) Database. <i>Clinical Oncology</i> , 2021 , 33, 57-63	2.8	2
70	Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021 , 278, 1179-1188	3.5	5
69	Clinical oncology module for the ESTRO core curriculum. <i>Radiotherapy and Oncology</i> , 2021 , 156, 19-22	5.3	1
68	The changing role of radiation oncology professionals in a world of AI - Just jobs lost - Or a solution to the under-provision of radiotherapy?. <i>Clinical and Translational Radiation Oncology</i> , 2021 , 26, 104-107	4.6	9
67	European white paper: oropharyngeal dysphagia in head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021 , 278, 577-616	3.5	16
66	ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016-2019). <i>Journal of Cancer Education</i> , 2021 , 1	1.8	2
65	Prognostic scoring models in parotid gland carcinoma. <i>Head and Neck</i> , 2021 , 43, 2081-2090	4.2	1
64	The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis. <i>Acta Oncologica</i> , 2021 , 60, 1534-1542	3.2	2
63	Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study. <i>Acta Oncologica</i> , 2021 , 60, 1472-1480	3.2	
62	Clinical Oncology Module for the ESTRO Core Curriculum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 111, e14	4	

61	Reply to Letter to the Editor regarding "In reference to Surgical treatment of the neck in patients with salivary gland carcinoma". <i>Head and Neck</i> , 2021 , 43, 3699-3700	4.2	
60	Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking. <i>Acta Oncologica</i> , 2020 , 59, 666-672	3.2	7
59	Exploring implementation of the ESTRO Core Curriculum at the national level. <i>Radiotherapy and Oncology</i> , 2020 , 147, 118-122	5.3	4
58	DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity. <i>Radiotherapy and Oncology</i> , 2020 , 148, 65-72	5.3	9
57	A randomized phase III trial for alleviating radiation-induced xerostomia with chewing gum. <i>Radiotherapy and Oncology</i> , 2020 , 142, 72-78	5.3	3
56	Reducing Late Dysphagia for Head and Neck Cancer Survivors with Oral Gel: A Feasibility Study. <i>Dysphagia</i> , 2020 , 35, 231-241	3.7	6
55	Prediction of radiation-induced mucositis of H&N cancer patients based on a large patient cohort. <i>Radiotherapy and Oncology</i> , 2020 , 147, 15-21	5.3	6
54	NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy. <i>Acta Oncologica</i> , 2019 , 58, 1410-1415	3.2	12
53	A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2019 , 58, 1495-1501	3.2	14
52	Up-front F18-FDG PET/CT in suspected salivary gland carcinoma. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 554-563	2.5	3
51	An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. <i>Apmis</i> , 2019 , 127, 240-264	3.4	16
50	Impact of age, comorbidity, and WHO performance status on delay of treatment in patients undergoing fast-track work-up for head and neck cancer. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 259-264	2.6	6
49	Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations. <i>Acta Oncologica</i> , 2019 , 58, 1373-1377	3.2	45
48	Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy. <i>Acta Oncologica</i> , 2019 , 58, 1366-1372	3.2	8
47	Recommended ESTRO Core Curriculum for Radiation Oncology/Radiotherapy 4th edition. <i>Radiotherapy and Oncology</i> , 2019 , 141, 1-4	5.3	17
46	Learning radiation oncology in Europe: Results of the ESTRO multidisciplinary survey. <i>Clinical and Translational Radiation Oncology</i> , 2018 , 9, 61-67	4.6	17
45	Local recurrences after curative IMRT for HNSCC: Effect of different GTV to high-dose CTV margins. <i>Radiotherapy and Oncology</i> , 2018 , 126, 48-55	5.3	22
44	IMRT - Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. <i>Oral Oncology</i> , 2018 , 86, 91-99	4.4	5

43	Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial. <i>Acta Oncologica</i> , 2018 , 57, 1159-1164	3.2	5
42	Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. <i>Supportive Care in Cancer</i> , 2017 , 25, 2179-2185	3.9	12
41	Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients. <i>Clinical and Translational Radiation Oncology</i> , 2017 , 2, 46-52	4.6	5
40	Defining a Leader Role curriculum for radiation oncology: A global Delphi consensus study. <i>Radiotherapy and Oncology</i> , 2017 , 123, 331-336	5.3	20
39	Postgraduate Education in Radiation Oncology in Low- and Middle-income Countries. <i>Clinical Oncology</i> , 2017 , 29, 129-134	2.8	10
38	Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods. <i>Acta Oncologica</i> , 2017 , 56, 1554-1561	3.2	14
37	Multidisciplinary training of cancer specialists in Europe. <i>European Journal of Cancer</i> , 2017 , 83, 1-8	7.5	15
36	Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanoma. <i>Acta Oncologica</i> , 2017 , 56, 109-110	3.2	6
35	Automatic treatment planning improves the clinical quality of head and neck cancer treatment plans. <i>Clinical and Translational Radiation Oncology</i> , 2016 , 1, 2-8	4.6	69
34	Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy. <i>Recent Results in Cancer Research</i> , 2016 , 198, 143-61	1.5	2
33	Primary mucosal melanoma of the head and neck in Denmark, 1982-2012: Demographic and clinical aspects. A retrospective DAHANCA study. <i>Acta Oncologica</i> , 2016 , 55, 1001-8	3.2	20
32	Trends in cancer of the head and neck in the elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , 2016 , 55 Suppl 1, 13-8	3.2	3
31	The Danish Head and Neck Cancer database. <i>Clinical Epidemiology</i> , 2016 , 8, 491-496	5.9	26
30	Xerostomia after Radiotherapy for Oral and Oropharyngeal Cancer: Increasing Salivary Flow with Tasteless Sugar-free Chewing Gum. <i>Frontiers in Oncology</i> , 2016 , 6, 111	5.3	9
29	Perspectives on medical education in radiation oncology and the role of the ESTRO School. <i>Clinical and Translational Radiation Oncology</i> , 2016 , 1, 15-18	4.6	9
28	An evaluation of multiplex bead-based analysis of cytokines and soluble proteins in archived lithium heparin plasma, EDTA plasma and serum samples. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016 , 76, 601-611	2	16
27	Open source deformable image registration system for treatment planning and recurrence CT scans : Validation in the head and neck region. <i>Strahlentherapie Und Onkologie</i> , 2016 , 192, 545-51	4.3	13
26	Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. <i>Acta Oncologica</i> , 2015 , 54, 1001-7	3.2	67

25	Establishing a Global Radiation Oncology Collaboration in Education (GRaCE): Objectives and priorities. <i>Radiotherapy and Oncology</i> , 2015 , 117, 188-92	5:3	12
24	Four years with FALCON - an ESTRO educational project: achievements and perspectives. <i>Radiotherapy and Oncology</i> , 2014 , 112, 145-9	5:3	35
23	Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. <i>Radiotherapy and Oncology</i> , 2014 , 113, 310-6	5:3	121
22	Still a long way to go to achieve multidisciplinary for the benefit of patients: commentary on the ESMO position paper (Annals of Oncology 25(1): 9-15, 2014). <i>Annals of Oncology</i> , 2014 , 25, 1863-1865	10:3	5
21	Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. <i>Radiotherapy and Oncology</i> , 2013 , 108, 489-94	5:3	42
20	The psychosocial work environment among physicians employed at Danish oncology departments in 2009. A nationwide cross-sectional study. <i>Acta Oncologica</i> , 2013 , 52, 138-46	3:2	8
19	The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology. <i>Radiotherapy and Oncology</i> , 2012 , 103, 103-8	5:3	61
18	The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. <i>Radiotherapy and Oncology</i> , 2011 , 100, 49-55	5:3	154
17	Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials. <i>Acta Oncologica</i> , 2011 , 50, 1006-14	3:2	45
16	Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. <i>Apmis</i> , 2010 , 118, 585-94 ^{3,4}		27
15	HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2010 , 94, 30-5	5:3	155
14	Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?. <i>Lancet Oncology, The</i> , 2010 , 11, 312-3	21:7	14
13	Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1992-8	2:2	482
12	Late onset of skin toxicity induced by EGFR-inhibitors. <i>Radiotherapy and Oncology</i> , 2009 , 90, 280-1	5:3	8
11	Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. <i>Radiotherapy and Oncology</i> , 2007 , 83, 389-97	5:3	71
10	Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. <i>Radiotherapy and Oncology</i> , 2007 , 83, 383-8	5:3	52
9	Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 2007 , 85, 24-8	5:3	34
8	Tumour hypoxia - a characteristic feature with a complex molecular background. <i>Radiotherapy and Oncology</i> , 2006 , 81, 119-21	5:3	14

7	Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. <i>Lancet Oncology, The</i> , 2005 , 6, 757-64	21.7	244
6	The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. <i>Radiotherapy and Oncology</i> , 2005 , 74, 93-100	5.3	82
5	The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. <i>Radiotherapy and Oncology</i> , 2005 , 76, 135-42	5.3	24
4	The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. <i>Acta Oncologica</i> , 2005 , 44, 50-8	3.2	24
3	The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 58, 561-6	4	92
2	Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. <i>Radiotherapy and Oncology</i> , 2004 , 72, 275-82	5.3	36
1	Esthesioneuroblastoma--what is the optimal treatment?. <i>Acta Oncologica</i> , 2000 , 39, 231-5	3.2	47